UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

October 1, 2015

(Date of Report - date of earliest event reported)

 

Arbutus Biopharma Corporation

(Exact Name of Registrant as Specified in Its Charter)

 

 

British Columbia, Canada (State or Other Jurisdiction of Incorporation or Organization)	001-34949 (Commission File Number)	98-0597776 (I.R.S. Employer Identification No.)
100-8900 Glenlyon Parkway Burnaby, British Columbia, Canada (Address of Principal Executive Offices)		V5J 5J8 (Zip Code)

 

(604) 419-3200

(Registrant's Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.02. Termination of a Material Definitive Agreement.

 

On October 1, 2015, we received formal notification of contract termination from the U.S. Department of Defense that our contract with the Department of Defense for the development of TKM-Ebola, an RNAi therapeutic utilizing our lipid nanoparticle technology to treat Ebola virus infection, was terminated, as expected, by the Department of Defense subject to the completion of our post-termination obligations contained therein.

 

As disclosed on July 20, 2015, the development activities related to TKM-Ebola were suspended per mutual agreement with the Department of Defense prior to receipt of the termination notice.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 1, 2015

 

 

		ARBUTUS BIOPHARMA CORPORATION
	By:	/s/ Bruce G. Cousins
		Name:	Bruce G. Cousins
		Title:	Executive Vice President & Chief Financial Officer